<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>BLOXIVERZ- neostigmine methylsulfateÂ injectionÂ </strong><br>Ã‰clat Pharmaceuticals, LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer"><span class="Bold">These highlights do not include all the information needed to use BLOXIVERZ safely and effectively.  See full prescribing information for BLOXIVERZ.
			<br>BLOXIVERZ<span class="Sup">â„¢</span> (Neostigmine Methylsulfate Injection), 
			<br>Initial U.S. Approval: 1939
		</span></div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">BLOXIVERZ, a <span class="product-label-link" type="condition" conceptid="4052720" conceptname="Acetylcholinesterase">cholinesterase</span> inhibitor, is indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents (NMBAs) after surgery  (<a href="#AL01079ee2111-d65c-11e1-9b23-0800200c9a66">1</a>). </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>Should be administered by trained healthcare providers (<a href="#SB021">2.1</a>)</li>
<li>Peripheral nerve stimulator and monitoring for twitch responses should be used to determine when BLOXIVERZ should be initiated and if additional doses are needed (<a href="#SB022">2.2</a>)
										<dl>
<dt>-</dt>
<dd>For reversal of NMBAs with shorter half-lives, when first twitch response is substantially greater than 10% of baseline, or when a second twitch is present:  <span class="Bold">0.03 mg/kg by intravenous route</span> (<a href="#SB022">2.2</a>)</dd>
<dt>-</dt>
<dd>For reversal of NMBAs with longer half-lives or when first twitch response is close to 10% of baseline:  <span class="Bold">0.07 mg/kg by intravenous route</span> (<a href="#SB022">2.2</a>)</dd>
</dl>
</li>
<li>Maximum total dosage is 0.07 mg/kg or up to a total of 5 mg (whichever is less) (<a href="#SB022">2.2</a>) </li>
<li>An anticholinergic agent, e.g., atropine sulfate or glycopyrrolate, should be administered prior to or concomitantly with BLOXIVERZ (<a href="#SB024">2.4</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Injection:  0.5 mg/mL and 1 mg/mL in 10 mL multiple-dose vials (<a href="#AL03079ee2111-d65c-11e1-9b23-0800200c9a66">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to neostigmine (<a href="#AL04079ee2111-d65c-11e1-9b23-0800200c9a66">4</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">Peritonitis</span> or mechanical obstruction of the intestinal or urinary tract (<a href="#AL04079ee2111-d65c-11e1-9b23-0800200c9a66">4</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li><span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>:  Atropine or glycopyrrolate should be administered prior to BLOXIVERZ to lessen risk of <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>. (<a href="#SB051">5.1</a>)</li>
<li>Serious Reactions with Coexisting Conditions:  Use with caution in patients with, <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>, recent <span class="product-label-link" type="condition" conceptid="4215140" conceptname="Acute coronary syndrome">acute coronary syndrome</span> or <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>. (<a href="#SB052">5.2</a>)</li>
<li>Neuromuscular Dysfunction:  Can occur if large doses of BLOXIVERZ are administered when <span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">neuromuscular blockade</span> is minimal; reduce dose if recovery from <span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">neuromuscular blockade</span> is nearly complete. (<a href="#SB054">5.4</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions during treatment: <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. (<a href="#AL06079ee2111-d65c-11e1-9b23-0800200c9a66">6</a>) </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Ã‰clat Pharmaceuticals at 1-877-622-2320 or FDA at 1-800-FDA-1088 or <span class="Italics Underline">www.fda.gov/medwatch</span>.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul><li>Pregnancy: No human or animal data.  Use only if clearly needed.</li></ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div><div></div></div>
<p class="HighlightsRevision">Revised: 12/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1. Â INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2. Â DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1.	Important Dosage Information</a></h2>
<h2><a href="#section-2.2" class="toc">2.2.	Dosage in Adults</a></h2>
<h2><a href="#section-2.3" class="toc">2.3.	Dosage in Pediatric Patients, including Neonates</a></h2>
<h2><a href="#section-2.4" class="toc">2.4.	Anticholinergic (Atropine or Glycopyrrolate) Administration</a></h2>
<h1><a href="#section-3" class="toc">3. Â DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4. Â CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5. Â WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1.	<span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2.	Serious Adverse Reactions in Patients with Certain Coexisting Conditions</a></h2>
<h2><a href="#section-5.3" class="toc">5.3.	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4.	Neuromuscular Dysfunction</a></h2>
<h2><a href="#section-5.5" class="toc">5.5.	<span class="product-label-link" type="condition" conceptid="4311957" conceptname="Cholinergic crisis">Cholinergic Crisis</span></a></h2>
<h1><a href="#section-6" class="toc">6. Â ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1.	Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2.	Post Marketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7. Â DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8. Â USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1. Â Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2. Â Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3. Â Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4. Â Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5. Â Geriatric Use</a></h2>
<h2><a href="#section-8.6" class="toc">8.6. Â <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.7" class="toc">8.7. Â <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10. Â OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11. Â DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12. Â CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1. Â Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2. Â Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3. Â Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13. Â NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1. Â Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14. Â CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16. Â HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="AL01079ee2111-d65c-11e1-9b23-0800200c9a66"></a><a name="section-1"></a><p></p>
<h1>1. Â INDICATIONS AND USAGE</h1>
<p class="First">BLOXIVERZ is a <span class="product-label-link" type="condition" conceptid="4052720" conceptname="Acetylcholinesterase">cholinesterase</span> inhibitor indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="AL02079ee2111-d65c-11e1-9b23-0800200c9a66"></a><a name="section-2"></a><p></p>
<h1>2. Â DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="SB021"></a><a name="section-2.1"></a><p></p>
<h2>2.1.	Important Dosage Information</h2>
<p class="First">BLOXIVERZ should be administered by trained healthcare providers familiar with the use, actions, characteristics, and complications of neuromuscular blocking agents (NMBA) and neuromuscular block reversal agents.  Doses of BLOXIVERZ should be individualized, and a peripheral nerve stimulator should be used to determine the time of initiation of BLOXIVERZ and should be used to determine the need for additional doses. </p>
<p>BLOXIVERZ is for intravenous use only and should be injected slowly over a period of at least 1 minute.  The BLOXIVERZ dosage is weight-based <span class="Italics">[see Dosage and Administration (<a href="#SB022">2.2</a>)]</span>.</p>
<p>Prior to BLOXIVERZ administration and until complete recovery of normal ventilation, the patient should be well ventilated and a patent airway maintained. Satisfactory recovery  should  be  judged by adequacy of skeletal muscle tone and respiratory measurements in addition to the response to peripheral nerve stimulation.</p>
<p>An anticholinergic agent, e.g., atropine sulfate or glycopyrrolate, should be administered prior to or concomitantly with BLOXIVERZ <span class="Italics">[see Dosage and Administration (<a href="#SB024">2.4</a>)]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SB022"></a><a name="section-2.2"></a><p></p>
<h2>2.2.	Dosage in Adults</h2>
<ol class="LittleAlpha">
<li>Peripheral nerve stimulation devices capable of delivering a train-of-four (TOF) stimulus are essential to effectively using BLOXIVERZ.</li>
<li>There must be a twitch response to the first stimulus in the TOF of at least 10% of its baseline level, i.e., the response prior to NMBA administration, prior to the administration of BLOXIVERZ. </li>
<li>Prior to administration, visually inspect BLOXIVERZ for particulate matter and discoloration.</li>
<li>BLOXIVERZ should be injected slowly by intravenous route over a period of at least 1 minute.</li>
<li>A 0.03 mg/kg to 0.07 mg/kg dose of BLOXIVERZ will generally achieve a TOF twitch ratio of 90% (TOF<span class="Sub">0.9</span>) within 10 to 20 minutes of administration. Dose selection should be based on the extent of spontaneous recovery that has occurred at the time of administration, the half-life of the NMBA being reversed, and whether there is a need to rapidly reverse the NMBA.
										<ul class="Disc">
<li>The 0.03 mg/kg dose is recommended for:
												<dl>
<dt>i.</dt>
<dd>Reversal of NMBAs with shorter half-lives, e.g., rocuronium, or</dd>
<dt>ii.</dt>
<dd>When the first twitch response to the TOF stimulus is substantially greater than 10% of baseline or when a second twitch is present.</dd>
</dl>
</li>
<li>The 0.07 mg/kg dose is recommended for 
												<dl>
<dt>iii.</dt>
<dd>NMBAs with longer half-lives, e.g., vecuronium and pancuronium, or </dd>
<dt>iv.</dt>
<dd>When the first twitch response is relatively weak, i.e., not substantially greater than 10% of baseline or</dd>
<dt>v.</dt>
<dd>There is need for more rapid recovery.</dd>
</dl>
</li>
</ul>
</li>
<li>TOF monitoring should continue to be used to evaluate the extent of recovery of neuromuscular function and the possible need for an additional dose of BLOXIVERZ.</li>
<li>TOF monitoring alone should not be relied upon to determine the adequacy of reversal of <span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">neuromuscular blockade</span> as related to a patientâ€™s ability to adequately ventilate and maintain a patent airway following tracheal extubation.</li>
<li>Patients should continue to be monitored for adequacy of reversal from NMBAs for a period of time that would assure full recovery based on the patientâ€™s medical condition and the pharmacokinetics of neostigmine and the NMBA used.</li>
<li>The recommended maximum total dose is 0.07 mg/kg or up to a total of 5 mg, whichever is less.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SB023"></a><a name="section-2.3"></a><p></p>
<h2>2.3.	Dosage in Pediatric Patients, including Neonates</h2>
<p class="First">Adult guidelines should be followed when BLOXIVERZ is administered to pediatric patients. Pediatric patients require BLOXIVERZ doses similar to those for adult patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SB024"></a><a name="section-2.4"></a><p></p>
<h2>2.4.	Anticholinergic (Atropine or Glycopyrrolate) Administration</h2>
<p class="First">An anticholinergic agent, e.g., atropine sulfate or glycopyrrolate, should be administered prior to or concomitantly with BLOXIVERZ. The anticholinergic agent should be administered intravenously using a separate syringe.  In the presence of <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, it is recommended that the anticholinergic agent be administered prior to BLOXIVERZ.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="AL03079ee2111-d65c-11e1-9b23-0800200c9a66"></a><a name="section-3"></a><p></p>
<h1>3. Â DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">BLOXIVERZ is available as</p>
<ul>
<li>Injection:  0.5 mg/mL, 5 mg of neostigmine methylsulfate in 10 mL multiple- dose vials</li>
<li>Injection:  1 mg/mL, 10 mg of neostigmine methylsulfate in 10 mL multiple-dose vials</li>
</ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="AL04079ee2111-d65c-11e1-9b23-0800200c9a66"></a><a name="section-4"></a><p></p>
<h1>4. Â CONTRAINDICATIONS</h1>
<p class="First">BLOXIVERZ is contraindicated in patients with:</p>
<ul>
<li>known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to neostigmine methylsulfate (known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> have included <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, generalized <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4133326" conceptname="Facial swelling">facial swelling</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>).</li>
<li>with <span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">peritonitis</span> or mechanical obstruction of the intestinal or urinary tract.</li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="AL05079ee2111-d65c-11e1-9b23-0800200c9a66"></a><a name="section-5"></a><p></p>
<h1>5. Â WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="SB051"></a><a name="section-5.1"></a><p></p>
<h2>5.1.	<span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span></h2>
<p class="First">Neostigmine has been associated with <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>.  Atropine sulfate or glycopyrrolate should be administered prior to BLOXIVERZ to lessen the risk of <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> <span class="Italics">[see Dosage and Administration (<a href="#SB024">2.4</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SB052"></a><a name="section-5.2"></a><p></p>
<h2>5.2.	Serious Adverse Reactions in Patients with Certain Coexisting Conditions</h2>
<p class="First">BLOXIVERZ should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>, recent <span class="product-label-link" type="condition" conceptid="4215140" conceptname="Acute coronary syndrome">acute coronary syndrome</span> or <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>.  Because of the known pharmacology of neostigmine methylsulfate as an acetylcholinesterase inhibitor, cardiovascular effects such as <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> or dysrhythmia would be anticipated.  In patients with certain cardiovascular conditions such as <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> or recent <span class="product-label-link" type="condition" conceptid="4215140" conceptname="Acute coronary syndrome">acute coronary syndrome</span>, the risk of blood pressure and heart rate complications may be increased.  Risk of these complications may also be increased in patients with <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>.  Standard antagonism with anticholinergics (e.g., atropine) is generally successful to mitigate the risk of cardiovascular complications.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SB053"></a><a name="section-5.3"></a><p></p>
<h2>5.3.	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First">Because of the possibility of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, atropine and medications to treat <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> should be readily available.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SB054"></a><a name="section-5.4"></a><p></p>
<h2>5.4.	Neuromuscular Dysfunction</h2>
<p class="First">Large doses of BLOXIVERZ administered when <span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">neuromuscular blockade</span> is minimal can produce neuromuscular dysfunction.  The dose of BLOXIVERZ should be reduced if recovery from <span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">neuromuscular blockade</span> is nearly complete.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SB055"></a><a name="section-5.5"></a><p></p>
<h2>5.5.	<span class="product-label-link" type="condition" conceptid="4311957" conceptname="Cholinergic crisis">Cholinergic Crisis</span></h2>
<p class="First">It is important to differentiate between myasthenic crisis and <span class="product-label-link" type="condition" conceptid="4311957" conceptname="Cholinergic crisis">cholinergic crisis</span> caused by overdosage of BLOXIVERZ.  Both conditions result in extreme <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> but require radically different treatment. <span class="Italics">[see Overdosage (<a href="#AL10079ee2111-d65c-11e1-9b23-0800200c9a66">10</a>)]</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="AL06079ee2111-d65c-11e1-9b23-0800200c9a66"></a><a name="section-6"></a><p></p>
<h1>6. Â ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="SB061"></a><a name="section-6.1"></a><p></p>
<h2>6.1.	Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. </p>
<p>Adverse reactions to neostigmine methylsulfate are  most often  attributable to exaggerated pharmacological effects, in particular, at muscarinic receptor sites. The use of an anticholinergic agent, e.g., atropine sulfate or glycopyrrolate, may prevent or mitigate these reactions.</p>
<p>Quantitative adverse event data are available from  trials of neostigmine methylsulfate in which 200 adult patients were exposed to the product. The following  table lists the  adverse reactions that occurred  with an overall frequency of 1% or greater. </p>
<table width="700"><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule"><span class="Bold">System Organ Class</span></td>
<td class="Botrule Lrule Rrule"><span class="Bold">Adverse Reaction</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><span class="Bold"><span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span></span></td>
<td class="Botrule Lrule Rrule"><span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>/heart rate increase</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span></td>
<td class="Botrule Lrule Rrule"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, post-<span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">procedural nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><span class="Bold">General Disorders and Administration <br>Site Conditions</span></td>
<td class="Botrule Lrule Rrule">incision site complication, pharyngolaryngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, procedural <br>complication, <span class="product-label-link" type="condition" conceptid="439502" conceptname="Postoperative pain">procedural pain</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></td>
<td class="Botrule Lrule Rrule"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="133088" conceptname="Late amputation stump complication">postoperative shivering</span>, prolonged <br><span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">neuromuscular blockade</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><span class="Bold">Psychiatric Disorders</span></td>
<td class="Botrule Lrule Rrule"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><span class="Bold">Respiratory, Thoracic and Mediastinal <br>Disorders</span></td>
<td class="Botrule Lrule Rrule"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, oxygen desaturation &lt;90%</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><span class="Bold">Skin and Subcutaneous Tissue Disorders</span></td>
<td class="Botrule Lrule Rrule"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span></td>
</tr>
</tbody></table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SB062"></a><a name="section-6.2"></a><p></p>
<h2>6.2.	Post Marketing Experience</h2>
<p class="First">The following adverse reactions have been identified during parenteral use of neostigmine methylsulfate. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<table width="700"><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule"><span class="Bold">System Organ Class</span></td>
<td class="Botrule Lrule Rrule"><span class="Bold">Adverse Reaction</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><span class="Bold">Allergic Disorders</span></td>
<td class="Botrule Lrule Rrule"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></td>
<td class="Botrule Lrule Rrule"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span>, <span class="product-label-link" type="condition" conceptid="4189159" conceptname="Muscle fibrillation">fasciculation</span>, loss of <br>consciousness, <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span>, visual changes</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><span class="Bold"><span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span></span></td>
<td class="Botrule Lrule Rrule"><span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> (A-V block, nodal rhythm), <br><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, nonspecific EKG changes, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><span class="Bold">Respiratory, Thoracic and Mediastinal <br>Disorders</span></td>
<td class="Botrule Lrule Rrule"><span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>; increased oral, pharyngeal and bronchial <br>secretions; <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>; <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><span class="Bold">Skin and Sub-cutaneous Tissue Disorders</span></td>
<td class="Botrule Lrule Rrule"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span></td>
<td class="Botrule Lrule Rrule"><span class="product-label-link" type="condition" conceptid="4091963" conceptname="Bowel spasm">bowel cramps</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, increased peristalsis </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><span class="Bold">Renal and Urinary Disorders</span></td>
<td class="Botrule Lrule Rrule"><span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><span class="Bold">Musculoskeletal and Connective Tissue <br>Disorders</span></td>
<td class="Botrule Lrule Rrule"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">spasms</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><span class="Bold">Miscellaneous</span></td>
<td class="Botrule Lrule Rrule"><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span></td>
</tr>
</tbody></table>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="AL07079ee2111-d65c-11e1-9b23-0800200c9a66"></a><a name="section-7"></a><p></p>
<h1>7. Â DRUG INTERACTIONS</h1>
<p class="First">The <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> between neostigmine methylsulfate and other drugs has not been studied.  Neostigmine methylsulfate is metabolized by microsomal enzymes in the liver.  Use with caution when using BLOXIVERZ with other drugs which may alter the activity of metabolizing enzymes or transporters.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="AL08079ee2111-d65c-11e1-9b23-0800200c9a66"></a><a name="section-8"></a><p></p>
<h1>8. Â USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="AL08179ee2111-d65c-11e1-9b23-0800200c9a66"></a><a name="section-8.1"></a><p></p>
<h2>8.1. Â Pregnancy</h2>
<p class="First">Teratogenic Effects:  Pregnancy Category C.  It is not known whether neostigmine methylsulfate can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity.  BLOXIVERZ should be given to a pregnant woman only if clearly needed.</p>
<p>Animal reproduction studies have not been conducted with neostigmine methylsulfate.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="AL08279ee2111-d65c-11e1-9b23-0800200c9a66"></a><a name="section-8.2"></a><p></p>
<h2>8.2. Â Labor and Delivery</h2>
<p class="First">The effect of BLOXIVERZ on the mother and fetus with regard to labor, delivery, the need for forceps delivery or other intervention or resuscitation of the newborn, is not known.  </p>
<p><span class="product-label-link" type="condition" conceptid="4052720" conceptname="Acetylcholinesterase">Cholinesterase</span> inhibitor drugs may induce <span class="product-label-link" type="condition" conceptid="4273560" conceptname="Premature labor">premature labor</span> when given intravenously to pregnant women near term.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="AL08379ee2111-d65c-11e1-9b23-0800200c9a66"></a><a name="section-8.3"></a><p></p>
<h2>8.3. Â Nursing Mothers</h2>
<p class="First">It is not known whether neostigmine methylsulfate is excreted in human milk.  Caution should be exercised when BLOXIVERZ is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="AL08479ee2111-d65c-11e1-9b23-0800200c9a66"></a><a name="section-8.4"></a><p></p>
<h2>8.4. Â Pediatric Use</h2>
<p class="First">BLOXIVERZ is approved for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery in pediatric patients of all ages.</p>
<p>Recovery of neuromuscular activity occurs more rapidly with smaller doses of <span class="product-label-link" type="condition" conceptid="4052720" conceptname="Acetylcholinesterase">cholinesterase</span> inhibitors in infants and children than in adults.  However, infants and small children may be at greater risk of complications from incomplete reversal of <span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">neuromuscular blockade</span> due to decreased respiratory reserve.  The risks associated with incomplete reversal outweigh any risk from giving higher doses of BLOXIVERZ (up to 0.07 mg/kg or up to a total of 5 mg, whichever is less).</p>
<p>The dose of BLOXIVERZ required to reverse <span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">neuromuscular blockade</span> in children varies between 0.03 mg - 0.07 mg/kg, the same dose range shown to be effective in adults, and should be selected using the same criteria as used for adult patients.   <span class="Italics">[see Clinical Pharmacology (<a href="#AL12379ee2111-d65c-11e1-9b23-0800200c9a66">12.3</a>)]</span></p>
<p>Since the blood pressure in pediatric patients, particularly infants and neonates, is sensitive to changes in heart rate, the effects of an anticholinergic agent (e.g., atropine) should be observed prior to administration of neostigmine to lessen the probability of <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="AL08579ee2111-d65c-11e1-9b23-0800200c9a66"></a><a name="section-8.5"></a><p></p>
<h2>8.5. Â Geriatric Use</h2>
<p class="First">Because elderly patients are more likely to have decreased renal function, BLOXIVERZ should be used with caution and monitored for a longer period in elderly patients. The duration of action of neostigmine methylsulfate is prolonged in the elderly; however, elderly patients also experience slower spontaneous recovery from neuromuscular blocking agents.  Therefore, dosage adjustments are not generally needed in geriatric patients; however, they should be monitored for longer periods than younger adults to assure additional doses of BLOXIVERZ are not required.  The duration of monitoring should be predicated on the anticipated duration of action for the NMBA used on the patient.  <span class="Italics">[see Dosage and Administration (<a href="#SB023">2.3</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="AL08679ee2111-d65c-11e1-9b23-0800200c9a66"></a><a name="section-8.6"></a><p></p>
<h2>8.6. Â <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Elimination half-life of neostigmine methylsulfate was prolonged in anephric patients compared to normal subjects.</p>
<p>Although no adjustments to BLOXIVERZ dosing appear to be warranted in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, they should be closely monitored to assure the effects of the neuromuscular blocking agent, particularly one cleared by the kidneys, do not persist beyond those of BLOXIVERZ.  In this regard, the interval for re-dosing the neuromuscular blocking agent during the surgical procedure may be useful in determining whether, and to what extent, post-operative monitoring needs to be extended.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="AL08779ee2111-d65c-11e1-9b23-0800200c9a66"></a><a name="section-8.7"></a><p></p>
<h2>8.7. Â <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">The pharmacokinetics of neostigmine methylsulfate in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> have not been studied.  Neostigmine methylsulfate is metabolized by microsomal enzymes in the liver.  No adjustments to the dosing of BLOXIVERZ appear to be warranted in patients with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>. However, patients should be carefully monitored if hepatically cleared neuromuscular blocking agents were used during their surgical procedure as their duration of action may be prolonged by <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> whereas BLOXIVERZ, which undergoes renal elimination, will not likely be affected.  This could result in the effects of the neuromuscular blocking agent outlasting those of BLOXIVERZ.  This same situation may arise if the neuromuscular blocking agent has active metabolites.  In this regard, the interval for re-dosing the neuromuscular blocking agent during the surgical procedure may be useful in determining whether, and to what extent, post-operative monitoring needs to be extended.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="AL10079ee2111-d65c-11e1-9b23-0800200c9a66"></a><a name="section-9"></a><p></p>
<h1>10. Â OVERDOSAGE</h1>
<p class="First">Muscarinic symptoms (<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, increased bronchial and salivary secretions, and <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>) may appear with overdosage of BLOXIVERZ (<span class="product-label-link" type="condition" conceptid="4311957" conceptname="Cholinergic crisis">cholinergic crisis</span>), but may be managed by the use of additional atropine or glycopyrrolate.  The possibility of iatrogenic <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> can be lessened by carefully monitoring the <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">muscle twitch</span> response to peripheral nerve stimulation.  Should overdosage occur, ventilation should be supported by artificial means until the adequacy of spontaneous respiration is assured, and cardiac function should be monitored.</p>
<p>Overdosage of BLOXIVERZ can cause <span class="product-label-link" type="condition" conceptid="4311957" conceptname="Cholinergic crisis">cholinergic crisis</span>, which is characterized by increasing <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, and through involvement of the muscles of respiration, may result in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.  Myasthenic crisis, due to an increase in the severity of the disease, is also accompanied by extreme <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> and may be difficult to distinguish from <span class="product-label-link" type="condition" conceptid="4311957" conceptname="Cholinergic crisis">cholinergic crisis</span> on a symptomatic basis.  However, such differentiation is extremely important because increases in the dose of BLOXIVERZ or other drugs in this class, in the presence of <span class="product-label-link" type="condition" conceptid="4311957" conceptname="Cholinergic crisis">cholinergic crisis</span> or of a refractory or â€œinsensitiveâ€? state, could have grave consequences.  The two types of crises may be differentiated by the use of edrophonium chloride as well as by clinical judgment.</p>
<p>Treatment of the two conditions differs radically.  Whereas the presence of myasthenic crisis requires more intensive anticholinesterase therapy, <span class="product-label-link" type="condition" conceptid="4311957" conceptname="Cholinergic crisis">cholinergic crisis</span> calls for the prompt withdrawal of all drugs of this type.  The immediate use of atropine in <span class="product-label-link" type="condition" conceptid="4311957" conceptname="Cholinergic crisis">cholinergic crisis</span> is also recommended.  Atropine may also be used to lessen gastrointestinal side effects or other muscarinic reactions; but such use, by masking signs of overdosage, can lead to inadvertent induction of <span class="product-label-link" type="condition" conceptid="4311957" conceptname="Cholinergic crisis">cholinergic crisis</span>.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="AL11079ee2111-d65c-11e1-9b23-0800200c9a66"></a><a name="section-10"></a><p></p>
<h1>11. Â DESCRIPTION</h1>
<p class="First">Neostigmine methylsulfate, a <span class="product-label-link" type="condition" conceptid="4052720" conceptname="Acetylcholinesterase">cholinesterase</span> inhibitor, is (<span class="Italics">m</span>-hydroxyphenyl) trimethylammonium methylsulfate dimethylcarbamate.  The structural formula is:</p>
<p><img alt="Structural Formula of Neostigmine Methylsulfate" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=79ee2111-d65c-11e1-9b23-0800200c9a66&amp;name=neostigmine-methylsulfate-figure-1.jpg"></p>
<p>Neostigmine methylsulfate is a white crystalline powder and is very soluble in water and soluble in alcohol.  BLOXIVERZ is a sterile, nonpyrogenic solution intended for intravenous use.</p>
<p>Each mL of the 0.5 mg/mL strength contains neostigmine methylsulfate 0.5 mg, phenol 4.5 mg (used as preservative) and sodium acetate trihydrate 0.2 mg, in water for injection.  The pH is adjusted, when necessary, with acetic acid/sodium hydroxide to a value of 5.5.</p>
<p>Each mL of the 1 mg/mL strength contains neostigmine methylsulfate 1 mg, phenol 4.5 mg (used as preservative), and sodium acetate trihydrate 0.2 mg, in water for injection.  The pH is adjusted, when necessary, with acetic acid/sodium hydroxide to achieve a value of 5.5.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="AL12079ee2111-d65c-11e1-9b23-0800200c9a66"></a><a name="section-11"></a><p></p>
<h1>12. Â CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="AL12179ee2111-d65c-11e1-9b23-0800200c9a66"></a><a name="section-11.1"></a><p></p>
<h2>12.1. Â Mechanism of Action</h2>
<p class="First">Neostigmine methylsulfate is a competitive <span class="product-label-link" type="condition" conceptid="4052720" conceptname="Acetylcholinesterase">cholinesterase</span> inhibitor. By reducing the breakdown of acetylcholine, neostigmine methylsulfate induces an increase in acetylcholine in the synaptic cleft which competes for the same binding site as nondepolarizing neuromuscular blocking agents, and reverses the <span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">neuromuscular blockade</span>.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="AL12279ee2111-d65c-11e1-9b23-0800200c9a66"></a><a name="section-11.2"></a><p></p>
<h2>12.2. Â Pharmacodynamics</h2>
<p class="First">Neostigmine methylsulfate-induced increases in acetylcholine levels results in the potentiation of both muscarinic and nicotinic cholinergic activity.  The resulting elevation of acetylcholine competes with nondepolarizing neuromuscular blocking agents to reverse <span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">neuromuscular blockade</span>.  Neostigmine methylsulfate does not readily cross the blood-brain barrier and, therefore, does not significantly affect cholinergic function in the central nervous system.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="AL12379ee2111-d65c-11e1-9b23-0800200c9a66"></a><a name="section-11.3"></a><p></p>
<h2>12.3. Â Pharmacokinetics</h2>
<p class="First"><span class="Italics">Distribution:</span>  Following intravenous injection, the observed neostigmine methylsulfate volume of distribution is reported between 0.12 and 1.4 L/kg.  Protein binding of neostigmine methylsulfate to human serum albumin ranges from 15 to 25%.</p>
<p><span class="Italics">Metabolism:</span>  Neostigmine methylsulfate is metabolized by microsomal enzymes in the liver.</p>
<p><span class="Italics">Elimination:</span>  Following intravenous injection, the reported elimination half-life of neostigmine methylsulfate is between 24 and 113 minutes.  Total body clearance of neostigmine methylsulfate is reported between 1.14 and 16.7 mL/min/kg. </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span>:</span>  Elimination half-life of neostigmine methylsulfate was prolonged in anephric patients compared to normal subjects; elimination half-life for normal, transplant and anephric patients were 79.8 Â± 48.6, 104.7 Â± 64 and 181 Â± 54 min (mean Â± SD), respectively.  </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic impairment</span>:</span>  The pharmacokinetics of neostigmine methylsulfate in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> has not been studied.  </p>
<p><span class="Italics">Pediatrics:</span>  Elimination half-life of neostigmine methylsulfate in infants (2-10 months), children (1-6 years) and adults (29-48 years) were 39 Â± 5 min, 48 Â± 16 min, and 67 Â± 8 min (mean Â± SD), respectively.  Observed neostigmine methylsulfate clearance for infants, children and adults were 14 Â± 3, 11 Â± 3 and 10 Â± 2 mL/min/kg (mean Â± SD), respectively.</p>
<p><span class="Italics">Drug Interaction Studies:</span>  The <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> between neostigmine methylsulfate and other drugs has not been studied.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="AL13079ee2111-d65c-11e1-9b23-0800200c9a66"></a><a name="section-12"></a><p></p>
<h1>13. Â NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="AL13179ee2111-d65c-11e1-9b23-0800200c9a66"></a><a name="section-12.1"></a><p></p>
<h2>13.1. Â Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><span class="Italics">Carcinogenesis:</span> Â Long-term animal studies have not been performed to evaluate the carcinogenic potential of neostigmine.</p>
<p><span class="Italics">Genotoxicity:</span> Â Neostigmine methylsulfate was not mutagenic or clastogenic when evaluated in an in vitro bacterial reverse mutation assay (Ames test), an in vitro Chinese hamster ovary cell chromosomal aberration assay, or an in vivo mouse bone marrow micronucleus assay.</p>
<p><span class="Italics">Impairment of Fertility:</span> Â Studies on the effect of neostigmine methylsulfate on fertility have not been performed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="AL14079ee2111-d65c-11e1-9b23-0800200c9a66"></a><a name="section-13"></a><p></p>
<h1>14. Â CLINICAL STUDIES</h1>
<p class="First">The evidence for the efficacy of neostigmine methylsulfate for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery is derived from the published literature.  Randomized, spontaneous-recovery or placebo-controlled studies using similar efficacy endpoints evaluated a total of 404 adult and 80 pediatric patients undergoing various surgical procedures. Patients had reductions in their recovery time from <span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">neuromuscular blockade</span> with neostigmine methylsulfate treatment compared to spontaneous recovery.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="AL16079ee2111-d65c-11e1-9b23-0800200c9a66"></a><a name="section-14"></a><p></p>
<h1>16. Â HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">BLOXIVERZ (Neostigmine Methylsulfate Injection, USP) is available in the following:</p>
<table class="Noautorules" width="550">
<col align="left" width="28%">
<col align="left" width="26%">
<col align="left" width="46%">
<tbody class="Headless">
<tr valign="top">
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="Bold">NDC No.</span></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="Bold">Strength</span></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="Bold">Vial Size</span></td>
</tr>
<tr valign="top">
<td class="Botrule Lrule Rrule Toprule" align="left">76014-002-10</td>
<td class="Botrule Lrule Rrule Toprule" align="left">0.5 mg/mL</td>
<td class="Botrule Lrule Rrule Toprule" align="left">10 mL multiple-dose vials (supplied in packages of 10)</td>
</tr>
<tr valign="top">
<td class="Botrule Lrule Rrule Toprule" align="left">76014-003-10</td>
<td class="Botrule Lrule Rrule Toprule" align="left">1 mg/mL</td>
<td class="Botrule Lrule Rrule Toprule" align="left">10 mL multiple-dose vials (supplied in packages of 10)</td>
</tr>
</tbody>
</table>
<p>The vial stopper is not made with natural rubber latex.</p>
<div class="Section" data-sectionCode="44425-7">
<a name="AL16179ee2111-d65c-11e1-9b23-0800200c9a66"></a><a name="section-14.1"></a><p></p>
<p class="First">BLOXIVERZ should be stored at 20Â° to 25Â°C (68Â° to 77Â°F); excursions permitted to 15Â° to 30Â°C (59Â° to 86Â°F) (see USP Controlled Room Temperature).  Protect from light.  Store in carton until time of use. </p>
<p>Â </p>
<p>Manufactured for:</p>
<p>Ã‰clat Pharmaceuticals</p>
<p>Chesterfield, MO 63005 USA</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="AL18079ee2111-d65c-11e1-9b23-0800200c9a66"></a><a name="section-15"></a><p></p>
<p class="First"><span class="Bold">Package Label - Principal Display Panel - Neostigmine Methylsulfate - 0.5 mg Vial - NDC 76014-002-33</span></p>
<p><img alt="Container Label - 0.5 mg Neostigmine Methylsulfate" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=79ee2111-d65c-11e1-9b23-0800200c9a66&amp;name=neostigmine-methylsulfate-figure-2.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="AL19079ee2111-d65c-11e1-9b23-0800200c9a66"></a><a name="section-16"></a><p></p>
<p class="First"><span class="Bold">Package Label - Principal Display Panel - Neostigmine Methylsulfate - 0.5 mg Carton - NDC 76014-002-33</span></p>
<p><img alt="Carton Box - 0.5 mg Neostigmine Methylsulfate" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=79ee2111-d65c-11e1-9b23-0800200c9a66&amp;name=neostigmine-methylsulfate-figure-3.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="SPDP008"></a><a name="section-17"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Package Label - Principal Display Panel - Neostigmine Methylsulfate â€“ 0.5 mg Ten Carton Package Flat Label - NDC 76014-002-10</span></p>
<p><img alt="Ten Carton Package Flat Label - 0.5 mg Neostigmine Methylsulfate" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=79ee2111-d65c-11e1-9b23-0800200c9a66&amp;name=neostigmine-methylsulfate-figure-8.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="PDP006"></a><a name="section-18"></a><p></p>
<p class="First"><span class="Bold">Package Label - Principal Display Panel - Neostigmine Methylsulfate â€“ 0.5 mg Ten Carton Package ECL - NDC 76014-002-10</span></p>
<p><img alt="Ten Carton Package ECL - 0.5 mg Neostigmine Methylsulfate" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=79ee2111-d65c-11e1-9b23-0800200c9a66&amp;name=neostigmine-methylsulfate-figure-6.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="AL20079ee2111-d65c-11e1-9b23-0800200c9a66"></a><a name="section-19"></a><p></p>
<p class="First"><span class="Bold">Package Label - Principal Display Panel - Neostigmine Methylsulfate - 1.0 mg Vial - NDC 76014-003-33</span></p>
<p><img alt="Container Label - 1.0 mg Neostigmine Methylsulfate" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=79ee2111-d65c-11e1-9b23-0800200c9a66&amp;name=neostigmine-methylsulfate-figure-4.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="AL21079ee2111-d65c-11e1-9b23-0800200c9a66"></a><a name="section-20"></a><p></p>
<p class="First"><span class="Bold">Package Label - Principal Display Panel - Neostigmine Methylsulfate - 1.0 mg Carton - NDC 76014-003-33</span></p>
<p><img alt="Carton Box - 1.0 mg Neostigmine Methylsulfate" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=79ee2111-d65c-11e1-9b23-0800200c9a66&amp;name=neostigmine-methylsulfate-figure-5.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="SPDP009"></a><a name="section-21"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Package Label - Principal Display Panel - Neostigmine Methylsulfate â€“ 1.0 mg Ten Carton Package Flat Label - NDC 76014-003-10</span></p>
<p><img alt="Ten Carton Package Flat  Label - 1.0 mg Neostigmine Methylsulfate" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=79ee2111-d65c-11e1-9b23-0800200c9a66&amp;name=neostigmine-methylsulfate-figure-9.jpg"></p>
<div class="Section" data-sectionCode="51945-4">
<a name="PDP007"></a><a name="section-21.1"></a><p></p>
<p class="First"><span class="Bold">Package Label - Principal Display Panel - Neostigmine Methylsulfate â€“ 1.0 mg Ten Carton Package ECL - NDC 76014-003-10 </span></p>
<p><img alt="Ten Carton Package ECL - 1.0 mg Neostigmine Methylsulfate" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=79ee2111-d65c-11e1-9b23-0800200c9a66&amp;name=neostigmine-methylsulfate-figure-7.jpg"></p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>BLOXIVERZÂ 		
					</strong><br><span class="contentTableReg">neostigmine methylsulfate injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:76014-002</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>NEOSTIGMINE METHYLSULFATE</strong> (NEOSTIGMINE) </td>
<td class="formItem">NEOSTIGMINE METHYLSULFATE</td>
<td class="formItem">0.5Â mg Â inÂ 1Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PHENOL</strong></td>
<td class="formItem">4.5Â mg Â inÂ 1Â mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM ACETATE</strong></td>
<td class="formItem">0.2Â mg Â inÂ 1Â mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ACETIC ACID</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:76014-002-10</td>
<td class="formItem">10  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:76014-002-33</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10 mL in 1 VIAL, MULTI-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA204078</td>
<td class="formItem">07/24/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>BLOXIVERZÂ 		
					</strong><br><span class="contentTableReg">neostigmine methylsulfate injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:76014-003</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>NEOSTIGMINE METHYLSULFATE</strong> (NEOSTIGMINE) </td>
<td class="formItem">NEOSTIGMINE METHYLSULFATE</td>
<td class="formItem">1Â mg Â inÂ 1Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PHENOL</strong></td>
<td class="formItem">4.5Â mg Â inÂ 1Â mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM ACETATE</strong></td>
<td class="formItem">0.2Â mg Â inÂ 1Â mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ACETIC ACID</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:76014-003-10</td>
<td class="formItem">10  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:76014-003-33</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10 mL in 1 VIAL, MULTI-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA204078</td>
<td class="formItem">07/24/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Ã‰clat Pharmaceuticals, LLC
							(965538205)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 12/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>d3e91f6c-b7de-4abb-a11f-6fbb42432fcc</div>
<div>Set id: 79ee2111-d65c-11e1-9b23-0800200c9a66</div>
<div>Version: 8</div>
<div>Effective Time: 20141204</div>
</div>
</div>Â <div class="DistributorName">Ã‰clat Pharmaceuticals, LLC</div></p>
</body></html>
